+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Mid-Career Research Award (MCRA)

Hemostasis & Thrombosis Research Society, Inc.

For clinicians, physician-scientists, or discovery-based scientists (MDs, DOs, PhDs, or MD/PhDs) with 5-to-15 years of academic research experience

The HTRS Mid-Career Research Award is for clinicians, physician-scientists, or discovery-based scientists (MDs, DOs, PhDs, or MD/PhDs) with 5-to-15 years of academic research experience.

It provides $216,000 in funding for two-year clinical, translational, or basic science research projects in hemostasis and/or thrombosis and is designed to assist recipients in making the transition to full academic research independence and R01-equivalent funding. Eligible applicants must demonstrate a commitment to academic research careers in classical hematology and fulfill the following requirements: have an MD, DO, PhD, MD/PhD, or equivalent doctoral degree, hold an academic faculty position at an institution in the U.S. or Canada, have had significant career development award funding, be working toward and eligible to receive a first R01 or equivalent in the U.S. or Canada, and demonstrate a clear path by which the MCRA will support submission of an R01 or equivalent in the U.S. or Canada.

Requirements

Award seekers must be HTRS Core-level members in good standing at the time of application.

AI Based Application Success Predictor

1. Strong focus on bleeding and thrombotic disorders

HTRS funding is tightly mission-driven. Competitive proposals clearly address:

Hemophilia A/B

von Willebrand disease

Rare bleeding disorders

Thrombosis, anticoagulation, and hemostasis biology

Complications such as inhibitors, thrombosis in special populations, or treatment safety

Top predictor: Direct, explicit relevance to hemostasis and thrombosis.

2. Clear fit to the specific HTRS award mechanism

HTRS offers distinct mechanisms, often emphasizing:

Early-career or trainee investigators

Mentored research

Pilot or feasibility studies

Successful applications explicitly state:

Why the project fits this HTRS award

How the scope matches the funding level and timeline

Predictor: Projects scaled appropriately (not NIH-sized) perform better.

3. Strong mentorship plan (for trainee / early-career awards)

For mentored awards, one of the strongest predictors of funding is:

A well-defined primary mentor with hemostasis expertise

Clear mentoring roles (scientific, career, clinical exposure)

Evidence the mentor has successfully trained investigators before

Red flag: Generic mentor letters or unclear mentoring structure.

4. Clear translational or clinical relevance

HTRS reviewers strongly favor projects that:

Improve understanding of bleeding/clotting mechanisms with clinical implications

Address unmet needs in diagnosis, treatment, or patient outcomes

Can inform future clinical trials or guideline-relevant work

Predictor: Bench-to-bedside framing, even for basic science projects.

5. Feasible methodology with a focused hypothesis

Historically successful HTRS grants:

Ask one clear primary question

Have well-defined endpoints

Use methods that are achievable within 1–2 years

Include realistic recruitment or sample access plans (for clinical studies)

Predictor: Simplicity + clarity > overly ambitious scope.

6. Applicant’s commitment to the field of hemostasis

Reviewers look for:

Prior abstracts, publications, or training in bleeding/thrombosis

Attendance or participation in HTRS or ISTH activities

A career trajectory aligned with hemostasis research

Predictor: Clear long-term engagement with the field.

7. Strong scientific rigor (even for pilot studies)

Even small HTRS grants succeed when they include:

Clear statistical reasoning or justification

Defined outcome measures

Plans for data analysis and interpretation

Predictor: Methodological seriousness, even at pilot scale.

8. Clear plan for dissemination and next-step funding

Successful proposals often state:

Plans to present findings at HTRS or ISTH meetings

Target journals

How the data will support future NIH, foundation, or industry funding

Predictor: Reviewers value HTRS funding as a launchpad.

❌ Common Reasons for Non-Selection

Weak connection to hemostasis/thrombosis

Overly broad or unfocused aims

Poorly developed mentorship plan

Project too large for the award size

Lack of applicant’s prior exposure to the field

Vague clinical relevance

Specialties

Clinical Trials

Hematology

Eligibility Requirements

For clinicians, physician-scientists, or discovery-based scientists (MDs, DOs, PhDs, or MD/PhDs) with 5-to-15 years of academic research experience

Eligible Countries:

Canada

United States

Sponsor Details

Sponsor Institute/Organizations: Hemostasis & Thrombosis Research Society, Inc.

Sponsor Type: Corporate/Non-Profit

Address: 8733 Watertown Plank Road Milwaukee, WI 53226-3548

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity